EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
47.65
+1.55 (3.36%)
At close: Apr 28, 2026
-22.27%
Market Cap 14.42B
Revenue (ttm) 1.01B
Net Income (ttm) -760.55M
Shares Out 302.65M
EPS (ttm) -2.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,216,153
Average Volume 1,056,495
Open 46.30
Previous Close 46.10
Day's Range 46.10 - 48.45
52-Week Range 43.50 - 84.30
Beta 0.67
RSI 32.71
Earnings Date May 8, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2025, EirGenix's revenue was 1.01 billion, a decrease of -0.38% compared to the previous year's 1.01 billion. Losses were -760.55 million, 8.91% more than in 2024.

Financial Statements

News

There is no news available yet.